HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT00257023

Paliperidone for schizophrenia

About this titleRead the official source — NCT00257023

This study evaluated the safety and effectiveness of paliperidone for people with schizophrenia.

Medication studyAges 20–64
The study in practice

Understand this study

What did researchers investigate?

This study evaluated the safety and effectiveness of paliperidone for people with schizophrenia.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 20 years to 64 years. Other eligibility criteria applied.

Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateFebruary 2005
Recruitment status
Completed
Enrollment listed in the registry
52
Sponsor
Janssen Pharmaceutical K.K.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Not clearly listed
Age range
From 20 Years to 64 Years
Official registry ID
NCT00257023
Official title
Show the full official title

Exploratory Study of Paliperidone in Patients With Schizophrenia to Investigate the Safety and Efficacy

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Locations not listed

Checked Official study record (opens in a new tab)
FAQ

Questions about this study

What did researchers investigate?

This study evaluated the safety and effectiveness of paliperidone for people with schizophrenia.

Who is behind this study?

The study sponsor is Janssen Pharmaceutical K.K., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including paliperidone.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 20 years to 64 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies